Atrial fibrillation (AF) is a major public health burden worldwide, and its prevalence is set to
increase owing to widespread population ageing, especially in rapidly developing countries …

Atrial fibrillation (AF) is the most prevalent arrhythmia and its incidence is on the rise. AF
causes significant morbidity and mortality leading to rising AF-related health care costs …

Background and objective Non-valvular atrial fibrillation (NVAF) increases the risk of
systemic thromboembolic events; therefore, anticoagulant treatment with vitamin K …

Background Stroke represents a major complication of atrial fibrillation (AF). The current
anticoagulation options for stroke prevention increase hemorrhage risk. The objective of the …

Background Stroke prevention is the main goal of treating patients with atrial fibrillation (AF).
Vitamin-K antagonists (VKAs) present an effective treatment in stroke prevention, however …

Non-valvular atrial fibrillation (NVAF) represents a major health-care problem, needing an
extensive and strict thrombosis prevention for stroke and cardiovascular (CV) disease risks …

Background The gene zinc finger homeobox 3 (ZFHX3) encodes a transcription factor with
cardiac expression and its genetic variants are associated with atrial fibrillation (AF). We …

Objective Determining the adherence to ACC/AHA/ESC 2006 guidelines and its influence
on the survival of patients with atrial fibrillation. Methods Prospective observational study of …

Abstract Background In the Netherlands, antihypertensive treatment for patients with mild
hypertension is recommended if the 10-year cardiovascular disease (CVD) risk exceeds …

Atrial fibrillation (AF) is the most common heart rhythm arrhythmia, which has considerable
economic consequences. This study aims to identify the current cost-of-illness estimates of …